{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:40:06Z","timestamp":1722386406897},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68199-9","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T13:02:31Z","timestamp":1722344551000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dementia incidence varied by anticancer drugs and molecular targeted therapy in a population-based cohort study"],"prefix":"10.1038","volume":"14","author":[{"given":"Eun Hye","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danbee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"68199_CR1","unstructured":"World Health Organization. Global action plan on the public health response to dementia 2017\u20132025. 44 p (World Health Organization, 2017)."},{"key":"68199_CR2","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/s0140-6736(15)00463-8","volume":"386","author":"JT O'Brien","year":"2015","unstructured":"O\u2019Brien, J. T. & Thomas, A. Vascular dementia. The Lancet 386, 1698\u20131706. https:\/\/doi.org\/10.1016\/s0140-6736(15)00463-8 (2015).","journal-title":"The Lancet"},{"key":"68199_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/alz.12308","volume":"17","author":"JD Chamberlain","year":"2021","unstructured":"Chamberlain, J. D. et al. Investigating the association between cancer and the risk of dementia: Results from the Memento cohort. Alzheimers Dement. 17, 1415\u20131421. https:\/\/doi.org\/10.1002\/alz.12308 (2021).","journal-title":"Alzheimers Dement."},{"key":"68199_CR4","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.jalz.2017.04.012","volume":"13","author":"L Frain","year":"2017","unstructured":"Frain, L. et al. Association of cancer and Alzheimer\u2019s disease risk in a national cohort of veterans. Alzheimers Dement. 13, 1364\u20131370. https:\/\/doi.org\/10.1016\/j.jalz.2017.04.012 (2017).","journal-title":"Alzheimers Dement."},{"key":"68199_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1212\/WNL.0b013e31829c5ec1","volume":"81","author":"M Musicco","year":"2013","unstructured":"Musicco, M. et al. Inverse occurrence of cancer and Alzheimer disease: A population-based incidence study. Neurology 81, 322\u2013328. https:\/\/doi.org\/10.1212\/WNL.0b013e31829c5ec1 (2013).","journal-title":"Neurology"},{"key":"68199_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e1442","volume":"344","author":"JA Driver","year":"2012","unstructured":"Driver, J. A. et al. Inverse association between cancer and Alzheimer\u2019s disease: Results from the Framingham Heart Study. BMJ 344, e1442. https:\/\/doi.org\/10.1136\/bmj.e1442 (2012).","journal-title":"BMJ"},{"key":"68199_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1212\/WNL.0b013e3181c91873","volume":"74","author":"CM Roe","year":"2010","unstructured":"Roe, C. M. et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74, 106\u2013112. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c91873 (2010).","journal-title":"Neurology"},{"key":"68199_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3233\/JAD-140168","volume":"42","author":"LL Ma","year":"2014","unstructured":"Ma, L. L. et al. Association between cancer and Alzheimer\u2019s disease: Systematic review and meta-analysis. J. Alzheimers Dis. 42, 565\u2013573. https:\/\/doi.org\/10.3233\/JAD-140168 (2014).","journal-title":"J. Alzheimers Dis."},{"key":"68199_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3233\/JAD-220436","volume":"89","author":"DD Zhang","year":"2022","unstructured":"Zhang, D. D. et al. Risk of dementia in cancer survivors: A meta-analysis of population-based cohort studies. J. Alzheimers Dis. 89, 367\u2013380. https:\/\/doi.org\/10.3233\/JAD-220436 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"68199_CR10","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1038\/s41598-019-49795-6","volume":"9","author":"S Seddighi","year":"2019","unstructured":"Seddighi, S., Houck, A. L., Rowe, J. B. & Pharoah, P. D. P. Evidence of a causal association between cancer and Alzheimer\u2019s disease: A mendelian randomization analysis. Sci. Rep. 9, 13548. https:\/\/doi.org\/10.1038\/s41598-019-49795-6 (2019).","journal-title":"Sci. Rep."},{"key":"68199_CR11","doi-asserted-by":"publisher","first-page":"1180905","DOI":"10.3389\/fgene.2023.1180905","volume":"14","author":"C Yuan","year":"2023","unstructured":"Yuan, C. et al. Causal association between colorectal cancer and Alzheimer\u2019s disease: A bidirectional two-sample mendelian randomization study. Front. Genet. 14, 1180905. https:\/\/doi.org\/10.3389\/fgene.2023.1180905 (2023).","journal-title":"Front. Genet."},{"key":"68199_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fonc.2020.00073","volume":"10","author":"M Sun","year":"2020","unstructured":"Sun, M., Wang, Y., Sundquist, J., Sundquist, K. & Ji, J. The association between cancer and dementia: A national cohort study in Sweden. Front. Oncol. 10, 73. https:\/\/doi.org\/10.3389\/fonc.2020.00073 (2020).","journal-title":"Front. Oncol."},{"key":"68199_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/alz.12090","volume":"16","author":"AG Ording","year":"2020","unstructured":"Ording, A. G. et al. Cancer and risk of Alzheimer\u2019s disease: Small association in a nationwide cohort study. Alzheimers Dement. 16, 953\u2013964. https:\/\/doi.org\/10.1002\/alz.12090 (2020).","journal-title":"Alzheimers Dement."},{"key":"68199_CR14","doi-asserted-by":"publisher","first-page":"7173","DOI":"10.1007\/s12035-019-1591-5","volume":"56","author":"KNH Nudelman","year":"2019","unstructured":"Nudelman, K. N. H., McDonald, B. C., Lahiri, D. K. & Saykin, A. J. Biological hallmarks of cancer in Alzheimer\u2019s disease. Mol. Neurobiol. 56, 7173\u20137187. https:\/\/doi.org\/10.1007\/s12035-019-1591-5 (2019).","journal-title":"Mol. Neurobiol."},{"key":"68199_CR15","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.4103\/1673-5374.332132","volume":"17","author":"HM Mansour","year":"2022","unstructured":"Mansour, H. M., Fawzy, H. M., El-Khatib, A. S. & Khattab, M. M. Repurposed anti-cancer epidermal growth factor receptor inhibitors: Mechanisms of neuroprotective effects in Alzheimer\u2019s disease. Neural Regen. Res. 17, 1913\u20131918. https:\/\/doi.org\/10.4103\/1673-5374.332132 (2022).","journal-title":"Neural Regen. Res."},{"key":"68199_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108171","volume":"237","author":"M Eshraghi","year":"2022","unstructured":"Eshraghi, M. et al. Enhancing autophagy in Alzheimer\u2019s disease through drug repositioning. Pharmacol. Ther. 237, 108171. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108171 (2022).","journal-title":"Pharmacol. Ther."},{"key":"68199_CR17","doi-asserted-by":"publisher","first-page":"13870","DOI":"10.1021\/acsomega.1c01526","volume":"6","author":"D Advani","year":"2021","unstructured":"Advani, D. & Kumar, P. Therapeutic targeting of repurposed anticancer drugs in Alzheimer\u2019s disease: Using the multiomics approach. ACS Omega 6, 13870\u201313887. https:\/\/doi.org\/10.1021\/acsomega.1c01526 (2021).","journal-title":"ACS Omega"},{"key":"68199_CR18","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00018-019-03428-3","volume":"77","author":"J Seo","year":"2020","unstructured":"Seo, J. & Park, M. Molecular crosstalk between cancer and neurodegenerative diseases. Cell Mol. Life Sci. 77, 2659\u20132680. https:\/\/doi.org\/10.1007\/s00018-019-03428-3 (2020).","journal-title":"Cell Mol. Life Sci."},{"key":"68199_CR19","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.3892\/ijo.2013.1882","volume":"42","author":"XL Du","year":"2013","unstructured":"Du, X. L., Cai, Y. & Symanski, E. Association between chemotherapy and cognitive impairments in a large cohort of patients with colorectal cancer. Int. J. Oncol. 42, 2123\u20132133. https:\/\/doi.org\/10.3892\/ijo.2013.1882 (2013).","journal-title":"Int. J. Oncol."},{"key":"68199_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/COC.0b013e3181b9cf1b","volume":"33","author":"XL Du","year":"2010","unstructured":"Du, X. L., Xia, R. & Hardy, D. Relationship between chemotherapy use and cognitive impairments in older women with breast cancer: Findings from a large population-based cohort. Am. J. Clin. Oncol. 33, 533\u2013543. https:\/\/doi.org\/10.1097\/COC.0b013e3181b9cf1b (2010).","journal-title":"Am. J. Clin. Oncol."},{"key":"68199_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100578","volume":"44","author":"J Kang","year":"2020","unstructured":"Kang, J. et al. Risk of dementia in prostate cancer survivors: A nationwide cohort study in Korea. Curr. Probl. Cancer 44, 100578. https:\/\/doi.org\/10.1016\/j.currproblcancer.2020.100578 (2020).","journal-title":"Curr. Probl. Cancer"},{"key":"68199_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244660","volume":"15","author":"M Shim","year":"2020","unstructured":"Shim, M. et al. Risk of dementia and Parkinson\u2019s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study. PLoS One 15, e0244660. https:\/\/doi.org\/10.1371\/journal.pone.0244660 (2020).","journal-title":"PLoS One"},{"key":"68199_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/andr.12187","volume":"4","author":"SD Chung","year":"2016","unstructured":"Chung, S. D. et al. Androgen deprivation therapy did not increase the risk of Alzheimer\u2019s and Parkinson\u2019s disease in patients with prostate cancer. Andrology 4, 481\u2013485. https:\/\/doi.org\/10.1111\/andr.12187 (2016).","journal-title":"Andrology"},{"key":"68199_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-023-01169-x","volume":"15","author":"B Dubois","year":"2023","unstructured":"Dubois, B. et al. Masitinib for mild-to-moderate Alzheimer\u2019s disease: Results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res. Ther. 15, 39. https:\/\/doi.org\/10.1186\/s13195-023-01169-x (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"68199_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-021-00831-6","volume":"13","author":"A Ancidoni","year":"2021","unstructured":"Ancidoni, A. et al. Anticancer drugs repurposed for Alzheimer\u2019s disease: A systematic review. Alzheimers Res. Ther. 13, 96. https:\/\/doi.org\/10.1186\/s13195-021-00831-6 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"68199_CR26","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1093\/eurheartj\/ehaa376","volume":"41","author":"J Kim","year":"2020","unstructured":"Kim, J. et al. Long-term \u03b2-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: Nationwide cohort study. Eur. Heart J. 41, 3521\u20133529. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa376 (2020).","journal-title":"Eur. Heart J."},{"key":"68199_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv319","volume":"46","author":"J Lee","year":"2017","unstructured":"Lee, J., Lee, J. S., Park, S. H., Shin, S. A. & Kim, K. Cohort profile: The national health insurance service-national sample cohort (NHIS-NSC) South Korea. Int. J. Epidemiol. 46, e15. https:\/\/doi.org\/10.1093\/ije\/dyv319 (2017).","journal-title":"Int. J. Epidemiol."},{"key":"68199_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2307\/2670170","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496\u2013509. https:\/\/doi.org\/10.2307\/2670170 (1999).","journal-title":"J. Am. Stat. Assoc."},{"key":"68199_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13195-020-00606-5","volume":"12","author":"D Newby","year":"2020","unstructured":"Newby, D. et al. Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study. Alzheimers Res. Ther. 12, 38. https:\/\/doi.org\/10.1186\/s13195-020-00606-5 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"68199_CR30","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.trci.2017.10.002","volume":"3","author":"A Judge","year":"2017","unstructured":"Judge, A. et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement. (N Y) 3, 612\u2013621. https:\/\/doi.org\/10.1016\/j.trci.2017.10.002 (2017).","journal-title":"Alzheimers Dement. (N Y)"},{"key":"68199_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.50","volume":"2","author":"CJ Garwood","year":"2011","unstructured":"Garwood, C. J., Pooler, A. M., Atherton, J., Hanger, D. P. & Noble, W. Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis. 2, e167. https:\/\/doi.org\/10.1038\/cddis.2011.50 (2011).","journal-title":"Cell Death Dis."},{"key":"68199_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21103483","volume":"21","author":"P Kozminski","year":"2020","unstructured":"Kozminski, P., Halik, P. K., Chesori, R. & Gniazdowska, E. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Int. J. Mol. Sci. 21, 1. https:\/\/doi.org\/10.3390\/ijms21103483 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"68199_CR33","doi-asserted-by":"publisher","first-page":"1238639","DOI":"10.3389\/fphar.2023.1238639","volume":"14","author":"HJ Choi","year":"2023","unstructured":"Choi, H. J., Jeong, Y. J., Kim, J. & Hoe, H. S. EGFR is a potential dual molecular target for cancer and Alzheimer\u2019s disease. Front. Pharmacol. 14, 1238639. https:\/\/doi.org\/10.3389\/fphar.2023.1238639 (2023).","journal-title":"Front. Pharmacol."},{"key":"68199_CR34","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/s41598-019-38676-7","volume":"9","author":"YJ Chen","year":"2019","unstructured":"Chen, Y. J. et al. Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation. Sci. Rep. 9, 2516. https:\/\/doi.org\/10.1038\/s41598-019-38676-7 (2019).","journal-title":"Sci. Rep."},{"key":"68199_CR35","doi-asserted-by":"publisher","first-page":"E3129","DOI":"10.1073\/pnas.1618804114","volume":"114","author":"BJ Wang","year":"2017","unstructured":"Wang, B. J. et al. ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer\u2019s disease. Proc. Natl. Acad. Sci. USA 114, E3129\u2013E3138. https:\/\/doi.org\/10.1073\/pnas.1618804114 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68199_CR36","doi-asserted-by":"publisher","first-page":"16743","DOI":"10.1073\/pnas.1208011109","volume":"109","author":"L Wang","year":"2012","unstructured":"Wang, L. et al. Epidermal growth factor receptor is a preferred target for treating amyloid-beta-induced memory loss. Proc. Natl. Acad. Sci. USA 109, 16743\u201316748. https:\/\/doi.org\/10.1073\/pnas.1208011109 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68199_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JAD-170429","volume":"60","author":"M Javidnia","year":"2017","unstructured":"Javidnia, M., Hebron, M. L., Xin, Y., Kinney, N. G. & Moussa, C. E. Pazopanib reduces phosphorylated tau levels and alters astrocytes in a mouse model of tauopathy. J. Alzheimers Dis. 60, 461\u2013481. https:\/\/doi.org\/10.3233\/JAD-170429 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"68199_CR38","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acschemneuro.5b00329","volume":"7","author":"L Huang","year":"2016","unstructured":"Huang, L. et al. Sunitinib, a clinically used anticancer drug, is a potent AChE inhibitor and attenuates cognitive impairments in mice. ACS Chem. Neurosci. 7, 1047\u20131056. https:\/\/doi.org\/10.1021\/acschemneuro.5b00329 (2016).","journal-title":"ACS Chem. Neurosci."},{"key":"68199_CR39","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.neuroscience.2009.05.019","volume":"162","author":"V Echeverria","year":"2009","unstructured":"Echeverria, V. et al. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 162, 1220\u20131231. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.05.019 (2009).","journal-title":"Neuroscience"},{"key":"68199_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/alz.062509","volume":"18","author":"B Eby","year":"2022","unstructured":"Eby, B. et al. Drug repurpose screening identifies regorafenib as potential amyloid-beta aggregation inhibitor. Alzheimer\u2019s Dement. 18, 1. https:\/\/doi.org\/10.1002\/alz.062509 (2022).","journal-title":"Alzheimer's Dement."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68199-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68199-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68199-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T13:04:55Z","timestamp":1722344695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68199-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68199"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68199-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17485"}}